{
    "clinical_study": {
        "@rank": "11501", 
        "arm_group": [
            {
                "arm_group_label": "Arm A (ipilimumab and rituximab)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 1, 4, 7, and 10. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "Arm B (ipilimumab and rituximab)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "This partially randomized phase I trial studies the side effects and best dose of ipilimumab\n      when given together with rituximab in treating patients with relapsed or refractory B-cell\n      lymphoma. Monoclonal antibodies, such as ipilimumab and rituximab, can block cancer growth\n      in different ways. Some block the ability of cancer cells to grow and spread. Others find\n      cancer cells and help kill them or carry cancer-killing substances to them."
        }, 
        "brief_title": "Ipilimumab and Rituximab In Treating Patients With Relapsed or Refractory B-Cell Lymphoma", 
        "condition": [
            "B-cell Adult Acute Lymphoblastic Leukemia", 
            "B-cell Chronic Lymphocytic Leukemia", 
            "Cutaneous B-cell Non-Hodgkin Lymphoma", 
            "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", 
            "Intraocular Lymphoma", 
            "Nodal Marginal Zone B-cell Lymphoma", 
            "Recurrent Adult Acute Lymphoblastic Leukemia", 
            "Recurrent Adult Burkitt Lymphoma", 
            "Recurrent Adult Diffuse Large Cell Lymphoma", 
            "Recurrent Adult Diffuse Mixed Cell Lymphoma", 
            "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", 
            "Recurrent Adult Grade III Lymphomatoid Granulomatosis", 
            "Recurrent Adult Hodgkin Lymphoma", 
            "Recurrent Adult Immunoblastic Large Cell Lymphoma", 
            "Recurrent Adult Lymphoblastic Lymphoma", 
            "Recurrent Grade 1 Follicular Lymphoma", 
            "Recurrent Grade 2 Follicular Lymphoma", 
            "Recurrent Grade 3 Follicular Lymphoma", 
            "Recurrent Mantle Cell Lymphoma", 
            "Recurrent Marginal Zone Lymphoma", 
            "Recurrent Small Lymphocytic Lymphoma", 
            "Refractory Chronic Lymphocytic Leukemia", 
            "Refractory Hairy Cell Leukemia", 
            "Small Intestine Lymphoma", 
            "Splenic Marginal Zone Lymphoma", 
            "Testicular Lymphoma", 
            "Waldenstr\u00f6m Macroglobulinemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Hodgkin Disease", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Hairy Cell", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphomatoid Granulomatosis", 
                "Waldenstrom Macroglobulinemia", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Large-Cell, Immunoblastic", 
                "Lymphoma, B-Cell, Marginal Zone", 
                "Lymphoma, Extranodal NK-T-Cell", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine a recommended phase II dose for ipilimumab in combination with rituximab.\n\n      SECONDARY OBJECTIVES:\n\n      I. To obtain preliminary information on the effect of adding ipilimumab to rituximab in\n      regard to: immune response; clinical anti-tumor response/overall remission rate (ORR)\n      (complete remission + partial remission); progression free survival (PFS).\n\n      OUTLINE: This is a dose-escalation study of ipilimumab followed by a randomized study.\n\n      PART I:\n\n      INDUCTION: Patients receive ipilimumab intravenously (IV) over 90 minutes once every 3 weeks\n      for 12 weeks and rituximab IV over 2-6 hours once weekly for 4 weeks.\n\n      MAINTENANCE: Patients receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours\n      once every 12 weeks for up to 1 year.\n\n      PART II: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive rituximab\n      IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in\n      weeks 1, 4, 7, and 10. Patients then receive ipilimumab IV over 90 minutes and rituximab IV\n      over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or\n      unacceptable toxicity.\n\n      ARM II: Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab\n      IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV\n      over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the\n      absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously treated, histologically confirmed cluster of differentiation (CD)20+ B\n             cell lymphoma; bone marrow biopsies as the sole means of diagnosis are not\n             acceptable, but they may be submitted in conjunction with nodal biopsies or extra\n             nodal biopsies; fine needle aspirates are not acceptable\n\n          -  All patients must be informed of the investigative nature of the clinical trial and\n             give written informed consent in accordance with institutional and federal guidelines\n\n          -  Able to adhere to the study visit schedule and other protocol requirements\n\n          -  Karnofsky >= 70%\n\n          -  Life expectancy expected to be greater than 3 months\n\n          -  Leukocytes >= 3,000/mcL\n\n          -  Absolute neutrophil count >= 1,000/mcL\n\n          -  Platelets >= 50,000/mcL\n\n          -  Total bilirubin =< 2.0 x institutional upper limit of normal\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 x institutional upper limit of normal\n\n          -  Serum creatinine =< 2.0 x upper limit of normal or calculated creatinine clearance >=\n             30 ml/min/1.73 M^2 by the modified Cockcroft and Gault Formula or creatinine\n             clearance >= 30 mL/min obtained from a 24-hour urine collection\n\n          -  At least one measurable lesion according to International workshop lymphoma response\n             criteria (Cheson 2007); there must be measurable lymphadenopathy to follow with\n             serial exam and/or imaging\n\n          -  All previous cancer therapy, including radiation, hormonal therapy and surgery, must\n             have been discontinued at least 4 weeks prior to treatment in this study\n\n          -  Patients must have evidence of progression of disease during or after last treatment\n\n          -  Submission of original biopsy for review and verification by Participating Center\n             hematopathologist\n\n          -  Disease free of prior malignancies for >= 3 years with exception of currently treated\n             basal cell, squamous cell carcinoma of the skin, or carcinoma \"in situ\" of the cervix\n             or breast\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for\n             nitrosoureas or mitomycin C) prior to entering the study or those who have not\n             recovered from adverse events due to agents administered more than 4 weeks earlier\n\n          -  Patients with a history of prior treatment with ipilimumab\n\n          -  Patients with a history of prior treatment with an anti-PD 1 antibody, CD137 agonist\n             or other immune activating therapy such as anti-CD 40 antibody are excluded unless 5\n             half-lives of the agent (minimum of 8 weeks) have intervened since the therapy;\n             patients who have received prior vaccine therapy are eligible\n\n          -  Patients who are receiving any other investigational agents\n\n          -  Autoimmune disease: patients with a history of inflammatory bowel disease, including\n             ulcerative colitis and Crohn's disease, are excluded from this study, as are patients\n             with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic\n             progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune\n             vasculitis [e.g., Wegener's Granulomatosis]); central nervous system (CNS) or motor\n             neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and\n             Myasthenia Gravis, multiple sclerosis)\n\n          -  Patients with known immune impairment who may be unable to respond to anti-cytotoxic\n             T-lymphocyte antigen 4 (CTLA 4) antibody\n\n          -  Patients with known brain metastases are excluded\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to rituximab\n\n          -  Patients on systemic corticosteroids (except for patients on stable doses of hormone\n             replacement therapy such as hydrocortisone), or other immunosuppressants (e.g.,\n             infliximab, mycophenolate mofetil) are excluded\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C\n             infections are excluded\n\n          -  Pregnant women are excluded from this study\n\n          -  HIV-positive patients on combination antiretroviral therapy are ineligible\n\n          -  Rituximab within six weeks"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01729806", 
            "org_study_id": "NCI-2012-02213", 
            "secondary_id": [
                "NCI-2012-02213", 
                "CDR0000743246", 
                "PHI-69", 
                "9197", 
                "U01CA062505", 
                "P30CA033572"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A (ipilimumab and rituximab)", 
                    "Arm B (ipilimumab and rituximab)"
                ], 
                "description": "Given IV", 
                "intervention_name": "ipilimumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody", 
                    "MDX-010", 
                    "MDX-CTLA-4", 
                    "monoclonal antibody CTLA-4"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (ipilimumab and rituximab)", 
                    "Arm B (ipilimumab and rituximab)"
                ], 
                "description": "Given IV", 
                "intervention_name": "rituximab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "IDEC-C2B8", 
                    "IDEC-C2B8 monoclonal antibody", 
                    "Mabthera", 
                    "MOAB IDEC-C2B8", 
                    "Rituxan"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (ipilimumab and rituximab)", 
                    "Arm B (ipilimumab and rituximab)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal", 
                "Cytotoxic T-lymphocyte antigen 4", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "contact": {
                    "email": "lpopplewell@coh.org", 
                    "last_name": "Leslie L. Popplewell", 
                    "phone": "626-256-4673"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Leslie L. Popplewell", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mohrbach@usc.edu", 
                    "last_name": "Ann Mohrbacher", 
                    "phone": "323-865-3924"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University of Southern California/Norris Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ann Mohrbacher", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Skhehler@cohmg.com", 
                    "last_name": "Stephen C. Koehler", 
                    "phone": "626-396-2900"
                }, 
                "facility": {
                    "address": {
                        "city": "Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91105"
                    }, 
                    "name": "City of Hope Medical Group Inc"
                }, 
                "investigator": {
                    "last_name": "Stephen C. Koehler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "joseph.tuscano@ucdmc.ucdavis.edu", 
                    "last_name": "Joseph M. Tuscano", 
                    "phone": "916-734-3771"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California at Davis Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Joseph M. Tuscano", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jeffreypu@hmc.psu.edu", 
                    "last_name": "Jeffrey J. Pu", 
                    "phone": "717-531-8399"
                }, 
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033-0850"
                    }, 
                    "name": "Penn State Milton S Hershey Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jeffrey J. Pu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma", 
        "overall_official": {
            "affiliation": "Beckman Research Institute", 
            "last_name": "Joseph Tuscano", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Tables will be created to summarize the toxicities and side effects by dose, course, organ and severity.", 
            "measure": "Incidence of toxicities according to the Common Terminology Criteria for Adverse Events version 4", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01729806"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Regression methods (adapted for repeated measures) will be used to describe the changes over time. In addition to summarizing the changes over time within each arm, these regression models will contain contrasts to compare the two arms in terms of changes.", 
                "measure": "Immune response as measured by the frequency of activated T-cells, absolute lymphocyte count, antibody dependent cell-mediated cytotoxicity, and kinetics and magnitude of B-cell depletion", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks"
            }, 
            {
                "measure": "Clinical anti-tumor response (complete response and partial response as per International workshop lymphoma response criteria [Cheson 2007])", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "description": "Progression-free survival will be summarized using Kaplan-Meier plots.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "From when the patient started treatment to the time the patient is first recorded as having disease relapse/progression, or to the date of death if the patient dies due to causes other than disease progression, assessed up to 12 months"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}